Plasma Fractionation Market

Analysis by Product {Immunoglobulins (Intravenous, and Subcutaneous), Coagulation Factors, and Albumin}; by Application (Immunology, Hematology, Critical Care, Rheumatology, and Neurology); and End-User (Hospitals, Clinical Research Lab, and Academic Institutes) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033

Buy Now
Report ID: 4548 | Published On: Feb 22, 2023
Request Free Sample Copy

Global Plasma Fractionation Market Size, Forecast, and Trend Highlights Over 2023 - 2033

The global plasma fractionation market is estimated to garner a revenue of ~USD 37 billion by the end of 2033 by growing at a CAGR of ~ 7% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 26 billion in the year 2022. The growth of the market is primarily attributed to the rising prevalence of bleeding disorders that occur when there is an issue that opposes the body’s blood clotting procedure. Based on the U. S. Centers for Disease Control estimates, there are nearly 3 million people nationwide, who have been suffering from bleeding disorders.

Plasma-Fractionation-Market-Scope.Get more information on this report:Download Sample PDF

Immunoglobulins are derived from the fractionation of plasma and are very effective in treating various neurologic, immunologic, and hematologic diseases. Hence, the increasing prevalence of immunological diseases among the population is anticipated to increase the need for immunoglobulins & alpha-1-antitrypsin in numerous areas of medicine. In addition to that, the increased focus on characterizing and diagnosing immunodeficiency is also expected to generate a high demand for plasma fractionation in the next few years owing to the high number of diagnosed patients. Further, another major factor expected to contribute to the growth of the market is the surge in plasma collection centers across the globe. For instance, a pioneer in the creation of plasma-derived medicines, Grifols has opened its 300th plasma donation site in the United States, the second in New England and the first in the state of Massachusetts.

Get more information on this report: Request Sample PDF

Global Plasma Fractionation Market: Key Insights

Base Year


Forecast Year



~ 7%

Base Year Market Size (2022)

~ USD 26 Billion

Forecast Year Market Size (2033)

~ USD 37 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Global Plasma Fractionation Market: Growth Drivers and Challenges

Growth Drivers

  • Proliferation in the Number of Chronic Diseases –There have been growing cases of chronic disease, which has increased the demand for its treatments. Among various treatments, plasma therapy is the most extensively used treatment. Hence, the plasma fractionation market is expected to grow further over the forecast period. For instance, the most common and expensive medical illnesses in the US are chronic diseases. About 133 million Americans, or roughly 45% of the population, have at least one chronic illness, and the number is rising.

  • Growing Geriatric Population – Old people have a weakened immune system and are prone to both chronic and acute diseases. Thus, for effective diagnostic and treatment procedures plasma fractionation has become imperative which is projected to create a positive outlook by the end of the forecast period. According to the World Health Organization figures, by 2030, one in every six persons on the planet would be 60 or older.

  • Increased Investment by Major Players in Effective Treatment – For instance, CSL Behring & Takeda Pharmaceutical Company Ltd. collaborated with Biotest, BPL, LFB, and Octapharma to develop an effective plasma-derived drug for the treatment of COVID-19.

  • Increasing Autoimmune Diseases - According to current estimates, the number of autoimmune disease cases worldwide is increasing between 3% to approximately 10% yearly.

  • Unhealthy Lifestyle Involving Consumption of Alcohol, Tobacco, and Fast Food – The recent shift of the population towards an unhealthy lifestyle has made the human body weak and with a low resistance to fight diseases and illnesses. As a result, for the diagnosing and treatment of these disorders, the demand for products from plasma fractionation is forecasted to increase in the upcoming years. According to the Centers for Disease Control and Prevention, 25.1% of adults aged 18 and over in the world are reported to have at least one day of heavy drinking (five or more drinks for males and four or more drinks for women) during the previous year.


  • High-Cost Related to Plasma Therapy - Plasma therapy is usually an expensive one, as it proves to be a lifesaver in severe cases where the patient has suffered trauma, burn, or severe kind of liver disorder and is in dire need of plasma. The recent scenario of the pandemic has also seen the great importance of plasma therapy such as convalescent plasma therapy, in the treatment of severe patients with Covid-19. For instance, it was observed in a clinical study that convalescent plasma was capable of substantially lower down the 28-day mortality and mechanical ventilation time of severe or critical COVID-19 patients. However, when plasma therapy is not given on time, usually when the symptoms are moderate, the cost is expected to increase, hence hindering the growth of the plasma fractionation market.
  • Increasing the Use of Recombinant Alternatives
  • Restricted Medical Reimbursement Policies

Market Segmentation

The global plasma fractionation market is segmented and analyzed for demand and supply by application into immunology, hematology, critical care, rheumatology, and neurology. Out of these, the neurology segment is anticipated to garner the largest revenue by the end of 2033, backed by increasing cases of neurological disorders such as Alzheimer, and Parkinson’s. According to the Pan America Health Organization, in 2019, neurological diseases were responsible for 533,172 deaths in the region, with men accounting for 213,129 (40%) and women accounting for 320,043 (60%). Also, the application of immunoglobulin is supposed to increase in the forecast period for treating cases of chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), myasthenia gravis, and inflammatory myopathies, thus expanding the segment share in the forecast period. Also, the rise in old age patients suffering from neurological disease across the globe along with increased research activities for using IVIG for neurology indications is another factor that is considered to bring growth opportunities.

The global plasma fractionation market is also segmented and analyzed for demand and supply by end-user in hospitals, clinical research labs, and academic institutes. Out of these, the hospitals segment is attributed generate the highest revenue during the forecast period. The major factor that is attributed to fuel the segment’s growth is the increasing adoption of plasma fractionation products in treating various disorders which includes autoimmune disease, neurological diseases, bleeding, and other disorders, along with the increased patient pool opting for plasma-derived therapies worldwide. Further, the growing number of hospitals in every region of the world and the presence of plasma donation centers in hospitals are also estimated to fuel the segment’s growth. Other growth factors for the segment development include rising investments in the hospital infrastructure, and the expansion of the healthcare sector.

Our in-depth analysis of the global plasma fractionation market includes the following segments:

         By Application

  • Immunology
  • Hematology
  • Critical Care
  • Rheumatology
  • Neurology

          By Product


  • Immunoglobulins
  • Coagulation Factors
  • Albumin

         By End-User

  • Hospitals
  • Clinical Research Lab
  • Academic Institutes

Global Plasma Fractionation Market Regional Synopsis

The North America plasma fractionation market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033. The high number of hemophilic patients along with the rising prevalence of other chronic diseases in the region is considered to be the major factor for the market growth in the region. In addition, the escalation in health disorders, including severe fever with thrombocytopenia syndrome (SFTS), hemophilia, and immune deficiencies, is also considered a growth factor for the market.

On the flip side, the European plasma fractionation market is also estimated to garner a significant share by the end of the assessment period. The major factors for the market growth in the region are attributed to the rising cases of immunodeficiency and bleeding disorders among Europeans. For instance, the total number of patient identified with a specific PI defect increased by 45.2% in Western Europe, and by 25.7% in Eastern Europe from 2013 to 2021.Furthermore, the increased count of blood plasma collection facilities across the region, and favorable regulations from the government are further propelling the growth of the plasma fractionation market over the assessment period in the region.


Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Global Plasma Fractionation Market

    • CSL Limited

      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Grifols, S.A.
    • Takeda Pharmaceutical Company Limited
    • Kedrion S.p.A
    • Octapharma AG
    • Bio Products Laboratory Ltd.
    • Biotest AG
    • LFB Group
    • Japan Blood Products Organization
    • Intas Pharmaceuticals Ltd. 

In The News

  • April 2022: IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
  • March 2022: Indegene a provider of technology-driven healthcare solutions, & meta Me Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the plasma fractionation market?

Ans: The major factors driving the growth of the market are increase In number of chronic diseases, growing geriatric population, increased investment by major players, and others.

2) What would be the CAGR of plasma fractionation market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2033.

3) What are the challenges affecting the plasma fractionation market growth?

Ans: High cost related to plasma therapy, increasing use of recombinant alternatives, and restricted medical reimbursement policies are some of the major factors expected to hinder the growth of the market.

4) Which region will provide more business opportunities for growth of plasma fractionation market in future?

Ans: The market in Europe is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

5) Who are the major players dominating the plasma fractionation market?

Ans: The major players in the market are CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, Kedrion S.p.A and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the plasma fractionation market?

Ans: The market is segmented by product, application, end-user, and by region.

8) Which segment captures the largest market size in application in the plasma fractionation market?

Ans: The neurology segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample